The week in pharma: action, reaction and insight – week to September 25, 2026

27 September 2026

By Barbara Obstoj-Cardwell. Managing editor

Important research news last week included US biotech Celldex Therapeutics releasing positive Phase III results for barzolvolimab for the treatment of spontaneous urticaria (CSU), while Roivant subsidiary Immunovant posted disappointing top-line trial results for its IMVT-1402 for the treatment of cutaneous lupus erythematosus (CLE). Also, Merck & Co released new data showing that its remigromig matched ranibizumab in diabetic macular edema. On the M&A front, Lexeo Therapeutics announced plans to acquire Mantle Therapeutics to expand its Friedreich ataxia platform.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK